273 Results

FDA approves Ontruzant biosimilar for all indications of Herceptin.- Samsung Bioepis + Merck Inc.

 Added 1 day ago

Samsung Bioepis Co., Ltd. announced that the FDA has approved Ontruzant (trastuzumab-dttb), a biosimilar referencing Herceptin (trastuzumab), across all eligible...

UK NICE recommends use of Verzenios in breast cancer.- Eli Lilly

 Added 4 days ago

The UK's NICE has recommended the use of Verzenios (abemaciclib), from Eli Lilly, for locally advanced or metastatic forms of...

Complete Response Letter for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer . Immunomedics

 Added 5 days ago

Immunomedics, Inc. announced it has received a Complete Response Letter (CRL) from the FDA for the Biologics License Application (BLA)...

Daiichi Sankyo initiates DESTINY-Breast 04 trial of[fam-] trastuzumab deruxtecan in patients with HER2 low, unresectable and/or metastatic breast cancer.

 Added 7 days ago

- Daiichi Sankyo Company, Limited announced that the first patient has been dosed in DESTINY-Breast04 , a global pivotal phase...

Eli Lilly announces publication of analyses showing benefit of Verzenio in multiple subgroups of patients with advanced breast cancer.

 Added 1 month ago

Eli Lilly and Company announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH...

FDA approves Herzuma (trastuzumab biosimilar) for breast cancer.- Celltrion + Teva.

 Added 1 month ago

Celltrion and Teva Pharmaceutical announced that the FDA has approved Herzuma (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to Herceptin (trastuzumab)...

Real-world data supports usage of Oncotype DX Breast Recurrence Score test in breast cancer.- Genomic Health.

 Added 1 month ago

Long-term outcomes data from a large population-based study further support the utility of the Oncotype DX Breast Recurrence Score test,...

Data analysis of MONALEESA trials shows efficacy and tolerability of Kisqali in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease.-Novartis

 Added 1 month ago

Novartis announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali (ribociclib) plus endocrine...

Study of Endopredict test shows influence on outcome in breast cancer.- Myriad Genetics.

 Added 1 month ago

Myriad Genetics announced the first prospective outcomes data on EndoPredict Test at the San Antonio Breast Cancer Symposium. This prospective...

Additional analysis of phase III SOLAR-1 trial of BYL 719 + fulvestrant PIK3CA mutated HR+/HER2- advanced or metastatic breast cancer.- Novartis

 Added 1 month ago

Novartis has announced additional analysis from the global Phase III SOLAR-1 trial investigating the alpha-specific PI3K inhibitor BYL 719 (alpelisib)...

Load more